• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    2.680 +0.110 (+4.28%)
    Official Closing Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,672,592
    Open 2.500
    Bid (Size) 2.740 (20)
    Ask (Size) 2.760 (9)
    Prev. Close 2.570
    Today's Range 2.450 - 2.710
    52wk Range 1.639 - 12.51
    Shares Outstanding 305,252,194
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Is Iovance Biotherapeutics Stock Due for a Big Rally?
    The biotech stock has been picking up steam of late -- but will it last? 
    Via The Motley Fool
    This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
    Even the average price estimate for this stock suggests it can soar, but not everyone's convinced. 
    Via The Motley Fool

    Performance

    YTD
    -65.6%
    -65.6%
    1 Month
    +53.1%
    +53.1%
    3 Month
    -23.4%
    -23.4%
    6 Month
    -54.2%
    -54.2%
    1 Year
    -67.2%
    -67.2%

    More News

    Read More
    Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Here are the top movers in Wednesday's session.
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    These stocks are gapping in today's session
    Via Chartmill
    Analyst Expectations For Iovance Biotherapeutics's Future
    Via Benzinga
    Health In Tech (NASDAQ: HIT) Posts Blowout Q2, Stock Responds – HIT, SNYR, PNPN.V/PNPNF in Breakout Zone; See More to Watch Inside
    Via AB Newswire
    Topics Artificial Intelligence
    Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
    Via Investor's Business Daily
    D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
    Via The Motley Fool
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Iovance Biotheapeutics, Inc. (IOVA) to Inquire About Their Rights in Class Action Lawsuit
    From Bragar Eagel & Squire
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky
    Via NewMediaWire
    Topics Fraud Lawsuit
    Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky
    Via TheNewswire.com
    Topics Fraud Lawsuit
    Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
    Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
    What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
    The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.680
    When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 08/01/25 04:00 PM ET
    What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 818.08M
    How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
    Iovance Biotherapeutics, Inc. - Common Stock has 818M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.